We are live on ! Find out more
ISL

Ingalls & Snyder LLC Portfolio holdings

AUM $2.83B
1-Year Est. Return 21.61%
This Fund
S&P 500
This Quarter Est. Return
+7.17%
1 Year Est. Return
+21.61%
3 Year Est. Return
+166.27%
5 Year Est. Return
+212.01%
10 Year Est. Return
+695.23%
AUM
$1.85B
AUM Growth
-$202M
Cap. Flow
-$288M
Cap. Flow %
-15.59%
Top 10 Hldgs %
31.04%
Holding
450
New
28
Increased
86
Reduced
211
Closed
50

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$59.2M
2
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$55.1M
3
BAC icon
Bank of America
BAC
+$21.4M
4
ABT icon
Abbott
ABT
+$16.5M
5
GL icon
Globe Life
GL
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 19.46%
2 Energy 16.48%
3 Industrials 10.8%
4 Financials 10.7%
5 Technology 9.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PXD
1
DELISTED
Pioneer Natural Resource Co.
PXD
$115M 6.23%
759,868
-43,351
-5% -$5.77M
CORT icon
2
Corcept Therapeutics
CORT
$9.72B
$97M 5.25%
8,014,351
-697,825
-8% -$9.71M
OMER icon
3
Omeros
OMER
$701M
$65.5M 3.55%
4,650,605
-373,150
-7% -$5.46M
CNQ icon
4
Canadian Natural Resources
CNQ
$91.5B
$59.3M 3.21%
3,742,351
-109,353
-3% -$1.49M
MSFT icon
5
Microsoft
MSFT
$2.93T
$53.3M 2.89%
338,082
-6,731
-2% -$989K
HXL icon
6
Hexcel
HXL
$7.83B
$39.7M 2.15%
541,750
-13,093
-2% -$1.01M
JPM icon
7
JPMorgan Chase
JPM
$907B
$38.9M 2.11%
279,044
-3,030
-1% -$389K
WMB icon
8
Williams Companies
WMB
$89.7B
$36.9M 2%
1,554,980
-119,883
-7% -$2.75M
PG icon
9
Procter & Gamble
PG
$349B
$33.9M 1.84%
271,720
-2,127
-0.8% -$260K
STRS icon
10
Stratus Properties
STRS
$165M
$33.9M 1.83%
1,092,868
-116,949
-10% -$3.35M
BMY icon
11
Bristol-Myers Squibb
BMY
$124B
$31.9M 1.73%
496,995
+102,242
+26% +$5.86M
C icon
12
Citigroup
C
$217B
$29.9M 1.62%
374,236
-5,101
-1% -$377K
DRRX
13
DELISTED
DURECT Corp
DRRX
$29.7M 1.61%
780,576
-38,480
-5% -$793K
CACC icon
14
Credit Acceptance
CACC
$6.69B
$27.8M 1.51%
62,939
-900
-1% -$397K
GOOGL icon
15
Alphabet (Google) Class A
GOOGL
$4.23T
$27.6M 1.5%
412,720
+1,060
+0.3% +$68.4K
MRK icon
16
Merck
MRK
$315B
$26.4M 1.43%
304,493
-1,005
-0.3% -$82.5K
GS icon
17
Goldman Sachs
GS
$314B
$25.4M 1.38%
110,619
-2,259
-2% -$490K
PFE icon
18
Pfizer
PFE
$143B
$24.1M 1.31%
648,866
+5,431
+0.8% +$193K
DAL icon
19
Delta Air Lines
DAL
$55.4B
$23M 1.25%
393,705
-12,400
-3% -$695K
JNJ icon
20
Johnson & Johnson
JNJ
$609B
$22.3M 1.21%
152,682
-738
-0.5% -$100K
ROP icon
21
Roper Technologies
ROP
$36.6B
$21.3M 1.15%
60,172
-860
-1% -$297K
CSCO icon
22
Cisco
CSCO
$441B
$21.2M 1.15%
441,927
+33,089
+8% +$1.54M
GOOG icon
23
Alphabet (Google) Class C
GOOG
$4.22T
$20.7M 1.12%
309,140
-2,780
-0.9% -$179K
CMPR icon
24
Cimpress
CMPR
$2.49B
$19.8M 1.07%
157,143
-2,280
-1% -$296K
PYPL icon
25
PayPal
PYPL
$49.9B
$18.5M 1%
171,023
-2,619
-2% -$273K

Similar funds

Ingalls & Snyder LLC's Q4 2019 Portfolio in Review

As of Q4 2019, Ingalls & Snyder LLC held 450 positions worth $1.85B, down 9.9% from $2.05B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Ingalls & Snyder LLC withdrew a net $288M in Q4 2019, closing 50 positions and reducing 211 holdings. Its most notable exit was Apple, an estimated $59.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 20% a quarter earlier, followed by Energy and Industrials.

Against the trend, Ingalls & Snyder LLC opened a new position in ROSETTA STONE INC worth $539K.

  • Ingalls & Snyder LLC's largest Q4 2019 buy was ROSETTA STONE INC: 29,710 shares worth $539K.
  • Ingalls & Snyder LLC added most to Bristol-Myers Squibb in Q4 2019, an estimated $5.86M increase.
  • Ingalls & Snyder LLC's biggest Q4 2019 reduction was Corcept Therapeutics, cutting an estimated $9.71M.
  • Ingalls & Snyder LLC fully exited Apple in Q4 2019, selling an estimated $59.2M.
  • Ingalls & Snyder LLC's ten largest holdings make up 31% of its $1.85B portfolio in Q4 2019.
  • Ingalls & Snyder LLC opened 28 new positions and closed 50 in Q4 2019.
  • Ingalls & Snyder LLC's portfolio value fell 9.9% quarter-over-quarter to $1.85B.

Based on Ingalls & Snyder LLC's 13F filing for Q4 2019, filed 15 Jan 2020.